vTv Therapeutics (NASDAQ:VTVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They issued a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Trading Down 0.2 %

NASDAQ:VTVT opened at $17.87 on Wednesday. The stock’s 50 day simple moving average is $14.89 and its 200-day simple moving average is $14.94. vTv Therapeutics has a 12-month low of $8.10 and a 12-month high of $30.99. The firm has a market cap of $57.01 million, a P/E ratio of -3.94 and a beta of 0.73.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) EPS for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC bought a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned approximately 5.92% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.